Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patientsThibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Cancers|March 14, 2026
Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in FranceGuillaume Meynard, Victor Pereira, Sophie Paget-Bailly, et al.
Cancer Causes & Control : CCC|January 26, 2022
To what extent do age, stage and treatment influence survival after invasive cervical cancer: a French population-based studyZoéwendtalé Cyrille Compaoré, Elisabeth Monnet, Aurélie Gérazime, et al.
Frontiers in Oncology|August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL StudyMagali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
BMJ Supportive & Palliative Care|December 31, 2024
Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibilityChloé Drozd, Quentin Jacquinot, Sophie Paget-Bailly, et al.
Future Oncology (London, England)|August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancerRayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
BMJ Oncology|January 31, 2025
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialLaurie Spehner, Emeline Orillard, Antoine Falcoz, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03Olivier Trédan, Delphine Loirat, Sylvie Chabaud, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)David Tougeron, Maxime Hentzien, Barbara Seitz-Polski, et al.
Pageof 5